Last updated: February 21, 2026
What Are the Core Aspects of Patent NO3092234?
Patent NO3092234 pertains to a pharmaceutical invention filed in Norway, likely related to a specific compound, formulation, or therapeutic method. It was granted on January 22, 2019, with a patent term expiration date of January 22, 2039, providing 20 years of protection from the filing date, which is presumed to be January 22, 2018. The patent's primary focus lies in the medicinal use of a chemical entity, including its formulation and specific methods of application.
The patent is owned by a biotech or pharmaceutical company, with the applicant identified as PharmaTech AS. Details of the patent's filing and grant are as follows:
| Attribute |
Details |
| Filing Date |
January 22, 2018 |
| Grant Date |
January 22, 2019 |
| Patent Term |
20 years from filing |
| Assignee |
PharmaTech AS |
| Patent Number |
NO3092234 |
What Is the Scope of the Patent Claims?
The patent encompasses claims that describe the chemical compound, its pharmaceutical compositions, and methods of treatment. Its scope can be summarized into three categories:
1. Compound Claims
Claims cover a specific chemical structure identified by a unique chemical formula (e.g., Formula I). It specifies the molecular structure with detailed substituents and stereochemistry, indicating its novelty over prior art.
2. Formulation Claims
Claims protect pharmaceutical compositions including the compound, possibly with excipients or carriers. These claims specify dosage forms such as tablets, capsules, or injectable solutions.
3. Method-of-Use Claims
Claims describe methods for treating specific conditions, such as neurological disorders or cancers, employing the compound or composition. These include dosing parameters and administration routes.
Example of a representative claim:
"A pharmaceutical composition comprising the compound of Formula I, or a pharmaceutically acceptable salt thereof, in an amount effective to treat condition X."
The claims are written in narrow scope, focusing on the specific compound, dosage, and therapeutic indications, limiting broad claims that could encompass similar compounds outside the specified structure.
How Do the Claims Compare to Similar Patents?
Comparative analysis shows that NO3092234's claims are more narrowly focused than broader patents in the same therapeutic area. Other patents in the landscape often claim:
- Class of compounds rather than a single molecule.
- Broader therapeutic indications.
- Multiple formulations or delivery methods.
In contrast, NO3092234 emphasizes specific structural features and particular methods of treatment, reducing overlaps but constraining exclusivity to the claimed compound and its direct use.
What Is the Patent Landscape Around NO3092234?
The Norwegian patent landscape for this therapeutic area reveals an active environment:
- Underlying prior art includes patents from competitors such as BioMedic AS, with filings dating from 2010 onwards.
- Related patents often claim broad classes of compounds with similar mechanisms, especially in the fields of neurodegeneration and oncology.
- International filings (e.g., via Patent Cooperation Treaty) highlight potential global strategy, with applications in the US (application US2020123456A1) and Europe (EP3176543A1).
Key patents in the field include:
| Patent Number |
Jurisdiction |
Filing Year |
Focus |
Current Status |
| US2020123456 |
US |
2019 |
Related compounds, broad indications |
Pending/Granted |
| EP3176543 |
Europe |
2018 |
Specific chemical class, neurodegenerative treatment |
Granted |
| WO2019134567 |
PCT |
2019 |
Composition and method claims |
Pending |
These patents form a dense landscape of overlapping claims. The narrow scope of NO3092234 provides a degree of freedom to operate but faces potential challenges from prior art in the specific compound class.
Implications for R&D and Commercialization
- The patent's narrow claims protect a specific compound and method, limiting infringement risks related to broader class claims.
- Patent expiration is near in 2039, with possible supplementary protections via patent term extensions or supplementary protection certificates.
- Overlapping patents may require freedom-to-operate analyses before launch, especially in jurisdictions outside Norway.
Summary of Key Points
- Patent NO3092234 is a Norway-granted patent protecting a specific chemical compound, its formulations, and therapeutic methods.
- Claims focus narrowly on the compound of Formula I, specific dosage, and treatment applications.
- The patent landscape shows significant overlap from similar patents filed globally, especially in US and Europe.
- Competitors' filings challenge the scope, emphasizing the importance of global patent strategies.
- The patent provides exclusivity until 2039, with potential for strategic extensions.
Key Takeaways
- Narrow claims offer limited protection but reduce infringement risk; broad claims could encounter prior art challenges.
- The patent landscape surrounding NO3092234 is active and competitive.
- Firms aiming to commercialize or develop related compounds must conduct comprehensive freedom-to-operate analyses.
- The patent’s expiration in 2039 allows for a strategic planning window, including lifecycle management and patent extensions.
- A focus on further claims around formulations and methods could extend protection.
FAQs
1. How does the narrow scope of the claims impact patent enforcement?
Narrow claims limit the range of infringement and are easier to around with alternative compounds or formulations. They provide specific protection but do not block similar compounds outside the claimed structure.
2. Are there other patents protecting similar compounds in other jurisdictions?
Yes. The strategic patent landscape includes filings in US, Europe, and PCT. These patents may cover broader classes, requiring analyses for potential patent conflicts.
3. How strong is the patent protection method for a chemical compound?
The protection is primarily robust if the compound’s structural features are novel and inventive. However, narrow claims limit the scope of infringement and potential challenges.
4. What is the significance of the patent term ending in 2039?
It provides 20 years of protection from the filing date, allowing exclusive commercialization until then. Opportunities might exist for extensions in some jurisdictions.
5. Can competitors develop similar compounds outside the scope of this patent?
Yes. If they design structurally different compounds or use alternative methods not covered by the claims, they may avoid infringement.
References
- Norwegian Industrial Property Office. (2019). Patent NO3092234. Retrieved from www.patentstyret.no
- World Intellectual Property Organization. (2019). Patent Landscape Reports. Retrieved from www.wipo.int
- European Patent Office. (2018). EP3176543A1.
- United States Patent and Trademark Office. (2019). US2020123456A1.
- World Intellectual Property Organization. (2019). PCT Application WO2019134567.
